MIAMI & BARRANQUILLA, Colombia - Procaps Group (NASDAQ: PROC), a prominent healthcare and pharmaceutical company in Latin America, announced today that it is exploring strategic alternatives to enhance shareholder value. The company is considering various options to accelerate growth, with the aim of optimizing returns for its shareholders.
Jose Vieira, the recently appointed CEO of Procaps, is developing a comprehensive strategic plan in collaboration with Ruben Minski, the Executive Chairman, and the company’s Board of Directors. Minski expressed confidence in Vieira's ability to formulate strategies that will position Procaps for a successful future.
To assist in this strategic review, Procaps has engaged BTG Pactual, a leading Latin American investment bank. Over the coming quarters, the bank will evaluate different alternatives. Additionally, a Strategic Committee has been established, led by Jose Minski and Alejandro Weinstein, both significant shareholders in Procaps, to ensure alignment between majority and minority shareholders. This committee has the authority to make recommendations to the Board of Directors.
Jose Minski voiced support for Vieira's transition into leadership and emphasized the committee's role in aiding him to identify the optimal strategy for shareholder benefit. Weinstein highlighted Procaps' commitment to reviewing strategic alternatives, including potential mergers and acquisitions, to maximize shareholder value while also ensuring positive outcomes for customers and employees.
Procaps has stated that there is no certainty about the results of this strategic review and has chosen not to provide further comments on the process. Future announcements will be made as required by ongoing disclosure obligations and applicable laws and regulations.
Procaps Group is a developer of pharmaceutical and nutraceutical solutions, delivering products to over 50 countries across all continents. With a workforce of more than 5,000, the company offers a range of over-the-counter and prescription medications, nutritional supplements, and clinical solutions.
This exploration of strategic alternatives is based on a press release statement from Procaps Group, and the company has made no further comments on the matter.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.